COVID-19 VACCINATION AND NATURAL INFECTION?S RESPONSES IN A COHORT of PATIENTS WITH INBORN ERROR of IMMUNITY FROM ARGENTINA

ERRA, LORENZO; URIARTE, IGNACIO; BEDROZNIK, LILIANA; ALMEJÚN MARÍA BELÉN

Mar del Plata

Congreso; Reunión Conjunta SAIC. SAI. SAFIS FAIC 2022; 2022

Sociedad Argentina de Inmunología

Patients with Inborn Errors of Immunity (IEI) in Argentina were encouraged to receive the authorized Sputnik, AstraZeneca, Sinopharm, Moderna and Pfizer vaccines. Most data on available vaccines derive from trials conducted on healthy individuals. Our aim was to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina.The study cohort included adults and pediatric IEI patients (n=118) and age-matched healthy-controls (HC) (n=37). Samples were collected before, 28+/-3 days after the first and the second doses (T2) of the vaccine. B-cell response was evaluated by measuring IgG anti-Spike(S)/RBD and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed at T2 with an alpha-S protein-expressing pseudo-virus assay. The T-cell response was analyzed by IFN-γ secretion on S or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) by flow cytometry.No moderate/severe vaccine-associated adverse events were observed. Regarding the antibody response, anti-S/RBD titers showed significant differences between IEI patients pediatric and adults with the age-matched HC cohort (p